These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. Gupta A; Jelinek HF; Al-Aubaidy H Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496 [TBL] [Abstract][Full Text] [Related]
8. Once-weekly glucagon-like peptide 1 receptor agonists. Kalra S; Gupta Y J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096 [TBL] [Abstract][Full Text] [Related]
10. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus. Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013 [TBL] [Abstract][Full Text] [Related]
11. New Injectable Drug for Type 2 Diabetes. Aschenbrenner DS Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319 [No Abstract] [Full Text] [Related]
12. Injectable combination therapies for the management of diabetes: an Indian perspective. Dutta D; Khandelwal D; Kalra S Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):209-216. PubMed ID: 32098522 [No Abstract] [Full Text] [Related]
13. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists? Darmon P; Raccah D Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016 [TBL] [Abstract][Full Text] [Related]
14. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist. Baron HL J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933 [TBL] [Abstract][Full Text] [Related]
15. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. Cariou B Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017 [TBL] [Abstract][Full Text] [Related]
16. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients? Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563 [No Abstract] [Full Text] [Related]
17. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455 [TBL] [Abstract][Full Text] [Related]
18. [Modern antihyperglycaemic agents--what is the patient benefit?]. Siegmund T MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585 [No Abstract] [Full Text] [Related]